Theranos whistleblower Tyler Shultz warns that the AI boom is ‘a great opportunity to go deceive people’

Tyler Shultz, whose first job out of college was at Theranos and who became a key whistleblower exposing its faulty blood-testing devices, told The San Francisco Standard that the AI boom is "a great opportunity to go deceive people." His warning arrives as a documentary about Theranos founder Elizabeth Holmes, "You Can See Everything," directed by Nathan Fielder and Lance Oppenheim, becomes one of the highest-grossing documentaries of all time and reignites public attention on the case. Holmes is serving a federal prison sentence of more than eleven years.
Shultz's core concern is diligence. He argues that AI is unusually hard to vet, telling the Standard it is difficult to tell "the difference between what is something truly unique and new versus like, a ChatGPT wrapper." That phrase refers to a product built mostly on top of a general-purpose model such as OpenAI's ChatGPT, with limited proprietary technology underneath. To an outside investor, a thin wrapper and a deep technical moat can present themselves in similar ways: both demo well, both can show impressive outputs, and neither necessarily exposes how much of the capability is borrowed.
Shultz ties the problem to funding behavior rather than technology alone. He said the era of a thirty-minute coffee leading to a $100,000 check should be over, describing Holmes as having scaled that model to $100 million. His grandfather, former Secretary of State and Treasury Secretary George Shultz, was a notable Theranos investor and board member. Shultz framed Holmes's raise as effectively the biggest angel round of all time, and argued that investors handing over that kind of money are granting founders tremendous power.
The Theranos comparison rests on specifics from the case. The company reached a peak valuation of around $10 billion even though its technology never worked as claimed; it ran only a fraction of tests on its own machines and outsourced the rest to third-party equipment. Its devices reached Walgreens stores and produced faulty results for real patients. Funding came largely from individual investors, including the DeVos and Walton families, rather than venture firms. Theranos withheld scientific evidence that its machines worked from prospective investors, citing trade-secret concerns, a stance that drove away many top Silicon Valley venture capitalists.
That history was widely read as a call for investors to prioritize due diligence. Shultz's worry is that the lesson fades as capital flows into AI companies that have never turned a profit but carry trillion-dollar valuations. In practice, diligence in AI is genuinely harder than in many other sectors: benchmarks can be gamed or overfit, demos can be curated, and a product's dependence on an underlying model provider may not be obvious from the outside. A likely trade-off is that investors who demand harder evidence may move more slowly and lose deals in a competitive market, while those who skip it accept risk that is difficult to price.
The documentary itself has drawn scrutiny for its framing. It deliberately avoids casting Holmes as either master manipulator or victim, focusing instead on her ability to draw pity even from people aware of her crimes. Critics note that it glosses over the most serious conduct, including faulty medical information given to patients and the harassment Shultz faced when he raised alarms inside and outside the company. The film also shows Holmes and her partner, hotel heir Billy Evans, working on a diagnostics venture called Haemanthus, described as "Theranos 2.0," which has reportedly raised about $20 million.
Shultz said he feels unease about what comes next, noting that Holmes is preparing a second act and that he does not know where it will lead. He also suggested that current attention to Holmes is itself partly a product of her own design, telling the Standard that the only reason people are discussing her now is that she wants them to be.
Why it matters: Founders and product teams building on top of foundation models should expect sharper questions about what is genuinely proprietary versus a thin layer over someone else's model, and investors are being pushed to demand technical evidence rather than rely on charisma and speed. If Shultz's concern holds, the practical effect is more scrutiny of benchmarks, architecture and customer proof during fundraising, which could slow some deals but reward teams that can show real differentiation. That is an inference from his remarks, not a stated prediction.
Based on reporting from the original publisher. Visit the source for full context and later updates.
Publisher excerpt
The cautionary Theranos tale takes on a new significance in the AI era, when companies that have never turned a profit are raising capital at trillion-dollar valuations.